Jiangsu Alpha Pharmaceutical Co., Ltd.

Products

tert-Butyl rosuvastatin

    • Product Name: tert-Butyl rosuvastatin
    • Chemical Name (IUPAC): tert-butyl (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonamido)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
    • CAS No.: 63503-86-6
    • Chemical Formula: C22H32FN3O6S
    • Form/Physical State: Solid
    • Factroy Site: Yinchuan, Ningxia, China
    • Price Inquiry: sales8@bouling-chem.com
    • Manufacturer: Jiangsu Alpha Pharmaceutical Co., Ltd.
    • CONTACT NOW
    VTB
    Specifications
    HS Code 494669
    Product Name tert-Butyl rosuvastatin
    Chemical Formula C28H46FN3O5S
    Molecular Weight 555.74 g/mol
    Cas Number 63503-86-6
    Appearance White to off-white solid
    Purity Typically >98%
    Storage Conditions Store at 2-8°C, protected from light
    Solubility Soluble in DMSO, methanol
    Application Pharmaceutical intermediate
    Synonyms Rosuvastatin tert-butyl ester
    Structure Type Ester derivative of rosuvastatin
    Iupac Name tert-butyl (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonamido)pyrimidin-5-yl](3,5-dihydroxyhept-6-enoate)
    Category Statin derivative
    Hazard Statements May cause irritation if inhaled or in contact with skin

    As an accredited tert-Butyl rosuvastatin factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing The packaging for tert-Butyl rosuvastatin (5 grams) is a sealed amber glass bottle, labeled with product details and safety information.
    Container Loading (20′ FCL) Container Loading (20′ FCL) for tert-Butyl rosuvastatin involves secure, bulk packaging, proper labeling, and compliance with chemical transport regulations.
    Shipping tert-Butyl rosuvastatin is shipped in secure, chemical-resistant containers, following regulatory guidelines for pharmaceutical intermediates. Packaging ensures protection from moisture, light, and temperature fluctuations. All shipments include proper labeling, safety documentation, and transport in compliance with international and local chemical transport regulations to maintain product integrity and safety during transit.
    Storage **tert-Butyl rosuvastatin** should be stored in a tightly sealed container, protected from moisture and light, at 2–8°C (refrigerated conditions). Store in a well-ventilated, dry place away from incompatible substances such as strong acids, bases, and oxidizing agents. Ensure proper labeling and avoid prolonged exposure to air. Follow all relevant safety regulations for chemical storage.
    Shelf Life The shelf life of tert-Butyl rosuvastatin is typically 2–3 years when stored in a cool, dry, and dark place.
    Application of tert-Butyl rosuvastatin

    Applications of tert-Butyl rosuvastatin in Industrial Manufacturing

    As a direct manufacturer of tert-butyl rosuvastatin, we support key pharmaceutical sector needs by supplying high-purity raw material for specialty statin synthesis. Our focus remains strictly within the pharmaceutical value chain, addressing only real-world, large-scale production environments where precise standards and formulation protocols are mandatory for consistent downstream outcomes.

    1. Bulk Synthesis of Rosuvastatin Calcium for Hypercholesterolemia Pharmaceuticals

    Downstream formulators use tert-butyl rosuvastatin as a core intermediate for synthesizing rosuvastatin calcium Active Pharmaceutical Ingredient (API) prescribed to lower LDL-C in cardiovascular risk patients. API manufacturers introduce tert-butyl rosuvastatin at a defined coupling stage, subjecting it to a series of chemical conversions under controlled conditions to ensure salt formation, high yield, and regulatory compliance for oral solid or injectable statin formulations. Reaction conditions and conversion protocols remain validated against pharmacopeial monographs to achieve consistent batch-to-batch quality that meets both regulatory and market expectations.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. API Quality Control Reference Material Production

    Pharmaceutical analytical labs and QC departments require internally consistent, high-purity reference standards for calibration and validation of chromatographic or spectrometric methods used during rosuvastatin calcium API release testing. tert-Butyl rosuvastatin, as a precursor and impurity marker, enters the reference material preparation workflow where traceability, documentation, and lot-to-lot consistency are paramount for pharmaceutical compliance.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Process Validation and Impurity Profiling for Statin APIs

    Chemical process development teams in statin API production rely on authentic tert-butyl rosuvastatin to model process impurity pathways and design effective purification protocols before full-scale cGMP launch. This application focuses on kinetic studies, degradation simulation, and stress testing, not just for initial validation, but for ongoing regulatory change control throughout the process lifecycle and scale-up phases.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Statin Finished Dosage Development for Generic Formulations

    Generic manufacturers that license or adapt statin formulation technology utilize tert-butyl rosuvastatin as a foundation for scale-up research and bridging studies. The intermediate enters laboratory-to-pilot program workflows, ensuring that both synthesis sequence and impurity profile match reference standards and supporting regulatory filings across international markets that increasingly demand equivalence demonstration.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive tert-Butyl rosuvastatin prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618005193850

    Email: sales8@bouling-chem.com

    Inquiry

    Get Free Quote of Jiangsu Alpha Pharmaceutical Co., Ltd.

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    tert-Butyl Rosuvastatin: Insights from Our Production Floor

    Understanding tert-Butyl Rosuvastatin

    Making tert-butyl rosuvastatin brings together deep experience in organic synthesis and a relentless commitment to reliability in the laboratory and at scale. Over the past decade, our chemists have handled statin derivatives across kilo labs and multi-ton reactors, guiding iterative improvements in purity, yield, and downstream handling. tert-Butyl rosuvastatin stands out as an essential intermediate, typically produced as a white to off-white crystalline powder, with high purity exceeding 99%, often backed by NMR, HPLC, and melting point data. While our process technology has changed over time thanks to feedback from formulation teams and global regulatory shifts, one constant has been minimizing byproduct formation and maintaining batch reproducibility. We keep a close eye on residual solvents and particulate matter, since any deviation can impact subsequent ester hydrolysis or scale-up reproducibility. Our current model standardizes the tert-butyl ester function, which simplifies deprotection at later stages and reduces concerns over undesired hydrolysis under humid storage.

    What sets tert-butyl rosuvastatin apart from earlier-generation statin intermediates is the balance it strikes between chemical stability and downstream reactivity. Comparing it to the methyl ester or free acid forms, the tert-butyl ester offers noticeably greater tolerance to both atmospheric moisture and short-term elevated temperatures, allowing greater flexibility in storage and shipment. Tight control of residual acid content and trace metals lets pharmaceutical partners focus on conversion yields rather than scavenging for process-related impurities. We settled on this profile not just for regulatory reasons, but from direct conversations with process chemists frustrated by batch-to-batch reprocessing headaches.

    The Science Driving Our Approach

    Colleagues from our pilot facility often revisit the early days of scale-up, recalling how problems with incomplete tert-butylation or poor crystallization led to lower yields and rising impurity profiles. Years of optimization followed, addressing not just solvent choice but also reflux control, filtration techniques, and handling of gaseous byproducts. On large scale, a controlled, solid-phase process with real-time impurity monitoring reduced batch failures. High-throughput analytical protocols caught intermediate oxidation products, so the final tert-butyl rosuvastatin consistently met pharmacopeial standards and performed reliably in downstream conversions.

    Our team often debates how granular model specification needs to be. Some partners want exhaustive impurity maps, others just seek regulatory batch records. Experience taught us to log more than the minimum required by ICH Q7 or USP standards; we track each significant peak on chromatograms, no matter how faint, and record results from both forced degradation and accelerated stability studies. Careful documentation controls polymorphism and helps keep patent and regulatory filings watertight.

    Details That Matter: Handling, Packaging, and Storage

    Over the years, we learned that the way tert-butyl rosuvastatin leaves our doors influences not just transport outcomes but how reliable downstream chemistry proceeds for our clients. Moisture management isn’t a trivial concern, since the tert-butyl ester provides a buffer but doesn’t eliminate risk; so, every order moves out under nitrogen, with desiccant-packed high-density polyethylene drums to cut down on hydrolytic activity. Specifications require tight resealability since even well-managed warehouses occasionally see humidity spikes. Adding tamper-evident bands wasn’t just for regulatory peace of mind—one lost drum in shipment reminded us how tracking from reactor to customer preserves traceability and resolves any rare but real disputes quickly.

    Granule sizing also reflects hands-on learning: too fine, and customers complain about bridging and dust; too coarse, and solubility lags in the next synthesis step. Our current standard targets a moderate flow, with blend testing using simulated downstream feeds to guarantee performance matches expectation. Outgassing profiles, monitored on randomly selected drums, provide further assurance that residual solvents stay below regulatory thresholds.

    Why tert-Butyl Rosuvastatin Remains Relevant

    As demand for safe, high-quality cholesterol-lowering drugs continues to rise, the world’s large formulators and specialty manufacturers face stricter quality regimes, more rigorous audits, and ever-shorter timelines for new product launches. tert-Butyl rosuvastatin’s utility comes from its dual nature: it’s stable enough to survive long global journeys and local warehousing, but remains chemically accessible for the final deprotection step, yielding rosuvastatin calcium or sodium salts. Direct experience handling customer feedback made clear that earlier forms—such as methyl esters—offered less stability against hydrolysis, resulting in yield loss or extra purification requirements. Our partners now specify tert-butyl, thanks to this history of real-world results, and our team remains close to the science so the compound keeps meeting changing demands.

    This intermediate acts as a strategic node in multistep syntheses. Its predictable reactivity, especially in basic or acidic conditions during the final deprotection, supports risk reduction at industrial scale. Project timelines experience fewer surprises, and R&D teams report smoother analytical validation, especially in tight regulatory windows for generics and novel formulations. We’ve observed how major method revisions often follow subtle changes in starting material profiles, so our production line keeps both batch-to-batch consistency and trace-level impurity monitoring at the forefront.

    Our Experience with Regulatory and Compliance Demands

    Pharma compliance keeps our team vigilant. Meeting expectations from agencies like the US FDA or EMA means documenting trace element content and solvent residuals to below established thresholds—processes we honed through hard lessons during major audits. Inspectors want evidence for GMP protocols that not just clean but prevent cross-contamination. Historical logbooks detail maintenance activities, cleaning cycles, filter changes, and batch segregation to satisfy authorities who understand that active pharmaceutical ingredient intermediates require traceability as well as robust analytics.

    We validate our control strategy through process simulation and destructive testing, periodically pushing production to extremes to make sure tert-butyl rosuvastatin stays within specification limits even during challenging runs. These “worst-case” tests allowed us to identify subtle process vulnerabilities, such as localized overheating that risked unwanted byproduct formation. Resolving these issues before market entry ensures our product stands up to regulatory questions at every checkpoint.

    Certification involves more than checklists. Inspectors interview operators and review electronic logbooks, so training and documentation cycles occur regularly. We coach new staff on handling substances like tert-butyl rosuvastatin with precision and safety in mind, teaching not just protocols but scientific rationales. Knowing the “why” behind each SOP fostered ownership and accountability across shifts.

    Adapting to Market Shifts and Customer Priorities

    The market for statin intermediates keeps evolving as generic competition fragments supply chains and new regional players enter the field. Customers no longer accept generic assurances—they want documented proof, tailored technical support, and flexibility in both packaging and just-in-time delivery. A few years ago, we partnered on custom batch sizes to fit smaller, tablet-centered operations that didn’t need ton quantities. Custom orders sometimes mean flexible granule sizing or modified drum packouts; technical support dives into solubility curves for uncommon process solvents.

    Raw material cost swings, especially in the tert-butylating agents, prompted us to invest in long-term supply agreements and backward integration. These arrangements helped stabilize output and hold prices steady for customers who plan multi-year projects. We also learned to communicate delays and market constraints honestly—customers adjust better with facts, not platitudes.

    The need for sustainability led to a review of solvent recovery and waste management. tert-Butyl rosuvastatin synthesis, like most pharmaceutical intermediates, generates process waste, but ongoing investments in recovery and recycling brought down both costs and environmental impact. Our process improvements, such as solvent distillation and byproduct neutralization, shaved months off environmental review cycles while aligning with wider ESG goals. Batch process audits now track and minimize solvent loss, with figures available for clients seeking to benchmark emissions.

    Addressing Customer Problems from Real Experience

    Customer calls sometimes reveal weak spots we simply don’t see from behind the reactor. One formulators’ feedback revealed that the moisture barrier on earlier packaging design didn’t last in a tropical climate, forcing a swift change to our secondary containment liner. The technical team developed new drum liners and augmented nitrogen flushing protocols. Occasional requests for data on trace metal content led us to adopt ICP-MS testing beyond usual specification points, capturing trace iron, copper, and zinc, since even low ppm contamination in intermediates can disrupt catalysis steps in downstream chemistry.

    Chemists scaling from gram to kilogram noticed a minor shift in HPLC retention time between batches; our root cause analysis—tracing back to a minor impurity in a key starting aldehyde—prompted us to revise sourcing, despite higher cost. That small correction eliminated the drift and kept our intermediate trusted in both legacy syntheses and emerging processes.

    Shipping delays sometimes cropped up at customs, especially with paperwork differing between countries. Our export and compliance staff started pre-vetting shipping documents and trained local forwarders to spot red flags before they could snowball into costly delays. Real-world supply chain problems teach agility; genuine responsiveness wins repeat business.

    Distinguishing tert-Butyl Rosuvastatin from Similar Materials

    Across hundreds of customer interactions, conversations often circle back to differences between tert-butyl rosuvastatin and other protected statin intermediates on the market. While all statin intermediates serve as stepping stones, tert-butyl ester versions offer superior hydrolytic stability than methyl or ethyl counterparts, making them less susceptible to acid/base-catalyzed deprotection during routine handling and shipping. This allows for more flexibility in formulation plant scheduling. In our own release testing, tert-butyl rosuvastatin maintains its integrity for longer periods under both accelerated and real-world conditions, compared to free acid forms, which showed higher rates of decomposition and water uptake.

    Handling convenience also makes a difference. Our manufacturing operators report smoother filtration and reduced tendency toward caking, thanks to the granular particle size we selected after investigating client complaints of dustiness with alternative intermediates. Analytical teams prefer the single, well-defined ester signal in NMR spectra, which assists with batch release and impurity tracking.

    We also compared tert-butyl and silyl-protected statin intermediates for select partnerships. While silyl groups sometimes offer higher reactivity, the added steps for silyl removal increased overall process complexity and introduced new sources of error. The tert-butyl route delivers a simpler deprotection with standard acid treatments, reducing both time and cost for partners focused on efficiency.

    Focus on Purity and Analytical Transparency

    Every facility producing pharmaceutical intermediates faces the challenge of revealing enough data to build trust while protecting proprietary process details. Our response involves providing comprehensive analytical packages with each shipment: full HPLC traces, melting point ranges, moisture analysis, and optional NMR summaries. Way back, supplying just certificate of analysis sufficed, but as compliance regimes grew stricter, analytical transparency became a deciding factor for long-term partnerships.

    For example, customers in Europe receiving tert-butyl rosuvastatin began requesting extended stability data for warehouse storage scenarios; we generated long-term data at multiple humidity points, updated annually, then shared this as part of new supplier audits. Transparent reporting reduced inbound testing delays at customer sites and lowered risk of shipment rejection.

    Continuous Improvement and Future Outlook

    Process innovation never stops. Production feedback loops—where our own engineers collaborate directly with pilot chemists and customer technical teams—drive ongoing gains in yield, waste minimization, and impurity control. Recent improvements in catalyst recovery advanced both process economics and batch quality, shrinking average process yields losses by nearly 2%. Some long-standing clients occasionally tour our facility and share their process bottlenecks, providing ground-level data that shapes both product and process evolution.

    Rapid shifts in pharmaceutical regulation, coupled with evolving intellectual property status for active statin ingredients, demand continual vigilance. Our regulatory affairs team tracks upcoming changes and manages tech transfer audits, giving partners confidence that tert-butyl rosuvastatin they purchase matches evolving legal and quality standards. Many industry observers believe newer analytical techniques, such as advanced mass spectrometry or real-time release testing, soon become requirements rather than options. We’re moving to validate these approaches, having already certified our existing QA/QC lines for batch traceability down to sub-ppm impurity levels.

    Safety Commitment and Worker Training

    Producing tert-butyl rosuvastatin safely takes more than equipment. Operators undergo specialized training on each process, especially during handling of tert-butyl esters and oxidizing agents, which present unique risks. We developed incident simulation workshops and ongoing assessment criteria, recognizing that real-world safety results spring from deep familiarity with compounds and procedures, not just rote memorization. Tracking leading indicators, such as equipment wear or solvent handling errors, reduces accident risk before reach incident status.

    A focus on safety culture also extends to periodic reviews of local fire and environmental controls, conducted alongside regulatory and internal auditors. This approach fostered a proactive safety mindset, significantly reducing downtime from both safety and compliance events.

    Value in Strategic Partnerships

    Working directly with global and regional pharmaceutical companies provided firsthand insight into how partners view tert-butyl rosuvastatin as a risk-mitigation tool within longer drug development pipelines. By maintaining consistent quality and responsive technical support, our teams helped downstream partners reduce the frequency of supply chain disruptions. For new partners entering the statin field, technical documentation and process guidance accelerate time-to-market, tapping into collective experience while building trust through demonstrated performance.

    Feedback loops with contract manufacturers and partners drive both incremental improvements—like improving batch size flexibility—and larger process overhauls, including digital inventory tracking and real-time shipment monitoring. These collaborations go beyond transactional exchanges, creating shared benefits that extend throughout the value chain.

    Conclusion

    tert-Butyl rosuvastatin reflects both technical mastery and the real-world lessons only sustained manufacturing provides. Our product carries forward years of incremental improvements, driven by science, operational feedback, regulatory demands, and above all, unfiltered conversations with the people who transform intermediates into lifesaving therapies for millions. As the statin field matures, our approach centers on controlled quality, transparent communication, and an unwavering focus on supporting innovators and formulators around the world.